Edesa Biotech Reports Fiscal Year 2021 Results tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial
$2.72
3.4%
Revenue increased by 35.9% to a record $86.85 million primarily driven by increased sales of stainless steel coil and strip and partially offset by decreased weighted average selling prices ( ASP ) offered to customers as a temporary sales strategy during the pandemic by providing one-off discount on certain products to some key customers.
Gross profit decreased by 74.8% to $3.94 million. Gross margin was 4.5%, compared to 24.5% for the prior fiscal year. The decreases in gross profit and gross margin were primarily due to increased sales percentage of low gross margin products such as stainless steel coil and strip and decreased sales percentage of high gross margin products such as stainless steel piping and fitting products.